Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein

  • A Bertoletti
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • F V Chisari
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • A Penna
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • S Guilhot
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • L Galati
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • G Missale
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • P Fowler
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • H J Schlicht
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • A Vitiello
    Cattedra Malattie Infettive, Università di Parma, Italy.
  • R C Chesnut
    Cattedra Malattie Infettive, Università di Parma, Italy.

書誌事項

公開日
1993-04
権利情報
  • https://journals.asm.org/non-commercial-tdm-license
DOI
  • 10.1128/jvi.67.4.2376-2380.1993
公開者
American Society for Microbiology

この論文をさがす

説明

<jats:p>Residues 11 to 27 of the hepatitis B virus nucleocapsid antigen contain a cytotoxic T-cell epitope that is recognized by cytotoxic T cells from virtually all HLA-A2-positive patients with acute hepatitis B virus infection. Using panels of truncated and overlapping peptides, we now show that the optimal amino acid sequence recognized by cytotoxic T cells is a 10-mer (residues 18 to 27) containing the predicted peptide-binding motif for HLA-A2 and that this peptide can stimulate cytotoxic T cells able to recognize endogenously synthesized hepatitis B core antigen. Since patients with chronic hepatitis B virus infection fail to mount an efficient cytotoxic T-cell response to it, this epitope might serve as the starting point for the design of synthetic peptide-based immunotherapeutic strategies to terminate persistent viral infection.</jats:p>

収録刊行物

  • Journal of Virology

    Journal of Virology 67 (4), 2376-2380, 1993-04

    American Society for Microbiology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ